BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8839667)

  • 1. Lack of interaction between orlistat and oral contraceptives.
    Hartmann D; Güzelhan C; Zuiderwijk PB; Odink J
    Eur J Clin Pharmacol; 1996; 50(5):421-4. PubMed ID: 8839667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pulsatile luteinizing hormone patterns in long term oral contraceptive users.
    Hemrika DJ; Slaats EH; Kennedy JC; de Vries Robles-Korsen TJ; Schoemaker J
    J Clin Endocrinol Metab; 1993 Aug; 77(2):420-6. PubMed ID: 8345046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
    Coates PE; Mesure R
    Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):47S-50S. PubMed ID: 7547095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy.
    Rosenfeld WE; Doose DR; Walker SA; Nayak RK
    Epilepsia; 1997 Mar; 38(3):317-23. PubMed ID: 9070594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The lack of interaction between temafloxacin and combined oral contraceptive steroids.
    Back DJ; Tjia J; Martin C; Millar E; Mant T; Morrison P; Orme M
    Contraception; 1991 Apr; 43(4):317-23. PubMed ID: 1906791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma concentrations of vasopressin and a prostaglandin F2 alpha metabolite in women with primary dysmenorrhoea before and during treatment with a combined oral contraceptive.
    Hauksson A; Akerlund M; Forsling ML; Kindahl H
    J Endocrinol; 1987 Nov; 115(2):355-61. PubMed ID: 3125302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Plasma concentrations of LH and of sex steroids during the normal menstrual cycle and during contraceptive treatment].
    Bayard F; Louvet JP; Moatti JP; Smilovici W; Duguet L; Boulard C
    J Gynecol Obstet Biol Reprod (Paris); 1975; 4(7):915-26. PubMed ID: 767402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omitting the first oral contraceptive pills of the cycle does not automatically lead to ovulation.
    Elomaa K; Rolland R; Brosens I; Moorrees M; Deprest J; Tuominen J; Lähteenmäki P
    Am J Obstet Gynecol; 1998 Jul; 179(1):41-6. PubMed ID: 9704763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory criteria for menopause in women using oral contraceptives.
    Creinin MD
    Fertil Steril; 1996 Jul; 66(1):101-4. PubMed ID: 8752618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA; Elkind-Hirsch KE; Malinak R
    Fertil Steril; 1996 Jul; 66(1):54-60. PubMed ID: 8752611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
    Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
    Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporary increase of FSH levels in healthy, nulliparous, young women after cessation of low-dose oral contraceptive use.
    Jernstrom H; Knutsson M; Olsson H
    Contraception; 1995 Jul; 52(1):51-6. PubMed ID: 8521715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R; Alfthan H; Haukkamaa M; Heikinheimo O; Luukkainen T; Lähteenmäki P
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No interaction between ciprofloxacin and an oral contraceptive.
    Scholten PC; Droppert RM; Zwinkels MG; Moesker HL; Nauta JJ; Hoepelman IM
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3266-8. PubMed ID: 9835524
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
    Griffith SG; Dai Y
    Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
    Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
    Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The efficacy of gestoden (delta 15-d-norgestrel) as ovulation inhibitor (author's transl)].
    Schneider WH; Schmid R; Spona J
    Wien Klin Wochenschr; 1981 Oct; 93(19):601-4. PubMed ID: 6798765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LH, FSH, estradiol and progesterone levels after discontinuation of hormonal contraception.
    Balogh A; Ditrói F; Lampé LG
    Acta Univ Palacki Olomuc Fac Med; 1981; 101():95-101. PubMed ID: 6242699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.